Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions comprising factor ó° and factor IXa for treating haemophilia

A composition, hemophilia technology, applied in blood diseases, drug combinations, extracellular fluid diseases, etc.

Inactive Publication Date: 2006-08-30
NAT INST FOR BIOLOGICAL STANDARDS & CONTROL
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, approximately 15% of hemophiliacs develop antibodies against factor VIII (Roberts, (1981), N. Engl. J. Med. 305, 757), which constitutes a major obstacle in the treatment of these patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions comprising factor ó° and factor IXa for treating haemophilia
  • Compositions comprising factor ó° and factor IXa for treating haemophilia
  • Compositions comprising factor ó° and factor IXa for treating haemophilia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0168] Materials and methods

[0169] Reagent

[0170] TBS buffer: 50 mM Tris, 150 mM NaCl, 0.02% NaN 2 , pH 7.4, 1% human serum albumin (Zenalb, BPL, Elstree, UK). Bovine fibrinogen (Diagnostic Reagents Ltd. Thame, Oxon UK). Lyophilized reagents from NIBSC, PottersBar, Herts, UK: phospholipids (91 / 542), recombinant FIXa (97 / 562), Agkistrodon antithrombotic enzyme (74 / 581), alpha-thrombin (89 / 588). FIXa reagent was 99% pure and was used to determine the presence or absence of FVIII and tissue factor in a factor Xa production system (Barrowcliffe TW, Fabregas P, Jardi M, Cancelas J, Rabaneda M, and Feize J. Procoagulant activity of Tlymphoblastoid cell due to exposure of negatively charged phosphoripid. Thromb Haemost 2002; 87: 442-449).

[0171] FVIII concentrate

[0172] A series of concentrates obtained with different purities and methods of preparation were studied. Effects The FVIII concentrate (Table 1) was lyophilized material, also obtained from NIBSC as a referen...

Embodiment 2

[0186] Dose response of TGT to FVIII

[0187] Concentrated HP(Mo-Ab)2 was spiked into artificially chemically depleted FVIII-deficient plasma with FVIII concentrations covering a wide range, from 0.005 to 1 IU / ml, and thrombin generation was measured (Fig 1A). When the concentration of FVIII was found to decrease from 1 to 0.005IU / ml, T1 / 2max The represented lag time was extended from 64 seconds to 165 seconds. However, despite very low levels of FVIII, peak thrombin was unaffected and only a small decrease in AUC was observed. Even when the concentration of FVIII was 0.005IU / ml, AUC was only slightly decreased compared with normal plasma, which were 6287 and 6540iu.sec, respectively. At a concentration of 1(T 1 / 2max 64sec) and 0.125IU / ml (T 1 / 2max 87sec), the ratio of thrombin to normal plasma (T 1 / 2max 118sec) produced faster, while the concentration of 0.03IU / ml (T 1 / 2max 119sec) was similar to that of normal plasma thrombin.

Embodiment 3

[0189] FVIII concentrate comparison

[0190] When different FVIII concentrates were added to FVIII-deficient plasma at the same FVIII:C concentration, the thrombin generation curves obtained were similar to those of the concentrate HP(Mo-Ab)2 ( figure 1 B, Table 2). All concentrates produced thrombin faster and in greater amounts than normal plasma at 1 IU / ml. T of rFVIII BDD 1 / 2max (48 sec) was shorter than the other concentrates (range 54-64 sec), this difference was statistically significant, p<0.05.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the use of FIXa and FVIII in the preparation of a composition for the treatment of haemophilia A or haemophilia B in a subject which does not present with anti-FVIII antibodies. The present invention further relates to a composition comprising FIXa and a composition comprising FVIII for simultaneous, simultaneous separate or sequential use in the treatment of haemophilia A or haemophilia B in a subject which does not present with anti-FVIII antibodies.

Description

field of invention [0001] The present invention relates to compositions for the treatment of hemophilia. [0002] Specifically, the present invention relates to the use of a composition containing FIXa and FVIII in the preparation of a composition for treating a subject with hemophilia A or B. Background of the invention [0003] The blood coagulation process involves a series of proteins called coagulation proteins that work in a cascade to cause the formation of a blood clot. [0004] The molecular mechanism of blood coagulation and the components involved in the coagulation process are described in detail in several review literatures (Furie, B. and Furie, B.C., Cell 53 (1988) 505-518; Davie, E.W. et al., Biochem. 30 (1991) 10363-10379; Bergmeyer, H.U. (ed.): Methods of Enzymatic Analysis, Vol. V, chapter 3, 3rd ed., Academic Press, New York (1983)). [0005] Hemophilia is a disease in humans and other mammals in which a gene encoding a blood clotting factor contains a ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/36A61K38/37A61P7/04
Inventor T·巴罗克利菲
Owner NAT INST FOR BIOLOGICAL STANDARDS & CONTROL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com